148 related articles for article (PubMed ID: 26576861)
21. [Molecular pathogenesis of peripheral T cell lymphoma (2): extranodal NK/T cell lymphoma, nasal type, adult T cell leukemia/lymphoma and enteropathy associated T cell lymphoma].
Couronné L; Bastard C; Gaulard P; Hermine O; Bernard O
Med Sci (Paris); 2015 Nov; 31(11):1023-33. PubMed ID: 26576610
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
Balagué O; Martínez A; Colomo L; Roselló E; Garcia A; Martínez-Bernal M; Palacín A; Fu K; Weisenburger D; Colomer D; Burke JS; Warnke RA; Campo E
Am J Surg Pathol; 2007 Sep; 31(9):1310-22. PubMed ID: 17721185
[TBL] [Abstract][Full Text] [Related]
23. Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.
Bachow SH; O'Connor OA
Clin Adv Hematol Oncol; 2015 Dec; 13(12):837-46. PubMed ID: 27058850
[TBL] [Abstract][Full Text] [Related]
24. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
25. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.
O'Connor OA; Bhagat G; Ganapathi K; Pedersen MB; D'Amore F; Radeski D; Bates SE
Clin Cancer Res; 2014 Oct; 20(20):5240-54. PubMed ID: 25320373
[TBL] [Abstract][Full Text] [Related]
26. Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study.
Farhan A; Chong EA; Schuster SJ; Strelec L; Nasta SD; Landsburg D; Svoboda J
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):109-115. PubMed ID: 30448048
[TBL] [Abstract][Full Text] [Related]
27. Peripheral T-cell lymphoma.
Foss FM; Zinzani PL; Vose JM; Gascoyne RD; Rosen ST; Tobinai K
Blood; 2011 Jun; 117(25):6756-67. PubMed ID: 21493798
[TBL] [Abstract][Full Text] [Related]
28. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes.
Allen PB; Pro B
Curr Oncol Rep; 2020 Apr; 22(5):44. PubMed ID: 32297075
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.
Pedersen MB; Hamilton-Dutoit SJ; Bendix K; Møller MB; Nørgaard P; Johansen P; Ralfkiaer E; Brown Pde N; Hansen PB; Jensen BA; Madsen J; Schöllkopf C; d'Amore F
Hematol Oncol; 2015 Dec; 33(4):120-8. PubMed ID: 25052551
[TBL] [Abstract][Full Text] [Related]
30. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management.
Marchi E; O'Connor OA
CA Cancer J Clin; 2020 Jan; 70(1):47-70. PubMed ID: 31815293
[TBL] [Abstract][Full Text] [Related]
31. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
[TBL] [Abstract][Full Text] [Related]
32. CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified.
Onaindia A; Martínez N; Montes-Moreno S; Almaraz C; Rodríguez-Pinilla SM; Cereceda L; Revert JB; Ortega C; Tardio A; González L; García S; Camacho FI; González-Vela C; Piris MA
Am J Surg Pathol; 2016 Mar; 40(3):378-85. PubMed ID: 26574847
[TBL] [Abstract][Full Text] [Related]
33. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.
Rodríguez J; Gutiérrez A; Martínez-Delgado B; Perez-Manga G
Crit Rev Oncol Hematol; 2009 Sep; 71(3):181-98. PubMed ID: 19056295
[TBL] [Abstract][Full Text] [Related]
34. Investigational drugs for the treatment of cervical cancer.
Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
[TBL] [Abstract][Full Text] [Related]
35. [Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)].
Kinoshita T
Nihon Rinsho; 2014 Mar; 72(3):512-8. PubMed ID: 24724412
[TBL] [Abstract][Full Text] [Related]
36. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
37. From empiric to mechanism-based therapy for peripheral T cell lymphoma.
Intlekofer AM; Younes A
Int J Hematol; 2014 Mar; 99(3):249-62. PubMed ID: 24510453
[TBL] [Abstract][Full Text] [Related]
38. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Watanabe T
Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic drugs against cancer: an evolving landscape.
Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L
Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708
[TBL] [Abstract][Full Text] [Related]
40. The spectrum of peripheral T-cell lymphomas.
O'leary H; Savage KJ
Curr Opin Hematol; 2009 Jul; 16(4):292-8. PubMed ID: 19509496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]